Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.30, read 2026-11-03
Ethical does not pass the values gate
Price55.71 USD
Fair value60.88
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-02Read Markup57.41-3.0% to today Accumulation gives way to Markup after a 12% rise in 7 days
2026-10-26Read Accumulation51.37+8.4% to today ✓Markdown gives way to Accumulation
2026-10-22Read Markdown51.37+8.4% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-11Read Accumulation51.58+8.0% to today ✓Markdown gives way to Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Kforce Inc. holds its Markup at $55.71. Consolidating, no directional conviction, held for 56 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 56 days
Price at the screen
$55.71
Valuation
24.33 trailing · 16.71 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.88
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
22.69%
Below 33%
Interest-bearing debt is just 22.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
52.68%
Below 49%
Money owed to the company is 52.7% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Kforce's business is fine, but its receivables are about 53% of its assets, just over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when KFRC's ethical verdict changes
Today KFRC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 4% discount to our $60.88 fair value, 4.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 8.5% discount to the base estimate.
Where our models see it going: fair-value estimate $60.88, with a range of $53.10 to $77.19, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Staffing Agency Priced for Growth It Lacks
Picture a recruiter placing tech and finance talent across US offices every week. The work feels essential yet Kforce shows zero revenue growth and just a 3 percent profit margin while asking investors to pay 20 times forward earnings.
We pass because the shares sit 20 percent above our fair value with no growth to justify the premium. High return on equity looks attractive on paper but flat sales and a modest margin leave little room for error when the economy softens.
The stock could stay expensive for a while if hiring demand holds but cyclical staffing businesses often see earnings peak at the same moment multiples compress. Ethical screen cleared yet the valuation leaves nothing on the table. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KFRC trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-02Markup · changed$57.41+11.8%Entry 17
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 45% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 45% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$51.37+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$51.37+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$51.37+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown · changed$51.37+0.0%Entry 12
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$51.37+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$51.37+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Accumulation$51.37+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$51.37-0.4%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it none, with a mean price target of $42.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.